U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

KIPE.		Applica	ation Number	10/601,03	36		
<sup>⊖</sup> TRANSMITTAL		Filing I		June 19,	2003		
AUG 2 9 2003 FORM			amed Inventor	<u> </u>	enneth W.		
(to be used sovall correspondence after in	itial filing)	Art Un					
TRADEMAN		-	ner Name				
Total Number of Pages in This Submission	Т		ey Docket Number	020552-0	03330US		
			S (Check all that appl				
Fee Transmittal Form	Drawin		o (oncer an arat app.		Nowance Communication to Group		
Fee Attached	Licensi	ng-relate	d Papers		I Communication to Board of Appeals terferences		
Amendment/Reply	Petition	ı		Appea Notice,	I Communication to Group (Appeal Brief, Reply Brief)		
After Final	_	onal App	ication	Proprie	etary Information		
Affidavits/declaration(s)			ey, Revocation espondence Address	Status	Letter		
Extension of Time Request	Termin	al Disclai	mer	Other (please	Enclosure(s) identify below):		
Express Abandonment Request	Reque			Return Por references	stcard, copies of five (5) cited		
Information Disclosure Statement				Í			
Certified Copy of Priority Document(s)	Rema	rks	The Commissioner is a Account 20-1430.	authorized to	charge any additional fees to Deposit		
Response to Missing Parts/ Incomplete Application			l				
Response to Missing Parts under 37 CFR 1.52 or 1.53							
SIG	NATURE O	F APPL	ICANT, ATTORNEY,	OR AGEN	IT		
Firm Townsend and Tow							
Individual Scott L. Ausenhus	or Scott Ausenhus		Reg. No	. 42,271			
Signature Scott	wen	Jul.					
Date August 25, 2003	Date August 25, 2003						
	CERTIFIC	ATE OF	TRANSMISSION/M.	AILING			
I hereby certify that this correspondence is being as first class mail in an envelope addressed to: C	facsimile trans ommissioner f	mitted to t or Patents	he USPTO or deposited wit P.O. Box 1450, Alexandria	h the United S I, VA 22313-14	states Postal Service with sufficient postage 450 on the date shown below.		
Typed or printed name Nicole M. Bur	ke						
Signature	JJE	Sw	LQ	Date	August 25, 2003		

This oddession of information is required by 37 CFR 1.6. The information is required to obtain or retain a benefit by the subtle which is to file (and by the USPTO process) an application. Conflicted retaining is generally \$1.5 USC 1.2 et and 37 CFR 1.4. This collection is estimated to take 12 minutes to complete, noting pathwing, preparing, and submitting the considered application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chef irreducing officer. U.S. Papart and Trademax Office, U.S. Department of Commerce, P.O. Box 1490, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patients, P.O. Box 1450, Alexandria, VA 22313-1450.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Attorney Docket No.: 020552-003330U

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

on Ave. 25,2003

TOWNSEND and TOWNSEND and CREW LLP

By: Nicole M Burke

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Kenneth Wood et al.

Application No.: 10/601,036

Filed: 06/19/2003

For: METHODS OF SCREENING FOR

MODULATORS OF CELL

PROLIFERATION

Examiner: not yet known

Art Unit: not yet known

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.97 and

\$1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. In accordance with 37 CFR §1.98(d), copies of all references, except for references A3, A4, C1, C12, and C34, can be found in Application No. 09/428,156, filed 10/27/1999 (Attorney Docket No. 020552-003300US). References A3, A4, C1, C12 and C34 are submitted herewith. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Kenneth Wood et al. Application No.: 10/601,036 Page 2

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that <u>no fee is required</u> for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Scott L. Ausenhus Reg. No. 42,271

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8<sup>th</sup> Floor San Francisco, California 94111-3834 Tel: 303-571-4000

Fax: 303-571-4321 SLA:nmb

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE ns are movined to rescond to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Red P Substitute for form 1449/PTO AUG 2 9 2003 INFORMATION DISCLOSUR STATEMENT BY ARBLICA

(use as many sheets as necessary)

of 5

Page

Compl te if Kn wn						
Application Number	10/601,036					
Filing Date	06/19/2003					
First Named Inventor	Wood, Kenneth W., et. al.					
Art Unit						
Examiner Name						
Attaca - Darelant Norman	020552 002220116					

U.S. PATENT DOCUMENTS							
Document Number							
Examiner	Cite No.	Number Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Palentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	A1	US-6,207,403	03-27-2001	Goldstein et al.			
	A2	US-6,410,254	06-25-2002	Finer et al.			
	A3	US-6,414,121 B1	07-02-2002	Wood et al.			
	A4	US-6,437,115 B1	08-20-2002	Wood et al.			

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Country Code <sup>3</sup>	reign Patent Document  Number <sup>4</sup> Kind Code <sup>6</sup> (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁰	
	B1	PCT	WO 95/18857	07/13/1995				
	B2	PCT	WO 99/34806	07/15/1999				
	B3	PCT	WO 00/07017	02/10/2000				
	B4	PCT	WO 00/63353	10/26/2000				
	B5	PCT	WO 01/07602	02/01/2001				

Examiner	Date
Signature	Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Kind Codes of U.S. Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Benter Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign onlight air sissed in document, by the two-ener doce years of the Emperor must precede the serial number of the patient document. Yind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 9 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of no persons are required to respond to a collection of information unless it contains a valid CMB control number G TRADE Substitute for form 1449/PTO Complete if Known **Application Number** 10/601.036 INFORMATION DISCLOSURE Filing Date 06/19/2003 STATEMENT BY APPLICANT First Named Inventor Wood, Kenneth W., et. al. Art Unit (use as many sheets as necessary) Examiner Name of 5 Page Attomey Docket Number 020552-003330US

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
	C1	BARTON "Protein Alignment and Database Scanning", <u>Protein Structure Prediction, A Practical Approach</u> , 1996, pp. 31-63, IRL Press at Oxford University Press, Oxford, UK.	
	C2	BLANGY et al. "Phosphorylation by p34cdc2 protein kinase regulates binding of the kinesin-related motor HsEg5 to the dynactin subunit p150", <i>Journal of Biol. Chem.</i> , 1997, pp. 19418-19424, Vol. 272.	
	СЗ	BLANGY et al. "Rigor-type mutation in the kinesin-related protein HsEg5 changes its subcellular localization and induces microtubule bundling", Cell Motil Cytoskeleton, 1998, pp. 174-182, Vol. 40.	
	C4	BLANGY, et al. "Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin- related motor essential for bipolar spindle formation in vivo", Cell, 1995, pp. 1159-1169, Vol. 83	
	C5	BURGESS, WILSON H., et al.; Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site- directed Mutagenesis of a Single Lysine Residue; The Journal of Cell Biology; November 1990; pp 2129-2138; Volume 111	
	C6	COLE et al. "A 'slow' homotetrameric kinesin-related motor protein purified from <i>Drosophila</i> embryos", J. Biol. Chem., 1994, pp. 22913-22916, Vol. 269.	
	C7	CREVEL et al. "Kinetic evidence for low chemical processivity in ncd and Eg5", J. Mol. Biol. , 1997, pp. 160-170, Vol. 273.	
	C8	DESAI et al. "Kin I kinesins are microtubule destabilizing enzymes", Cell, 1999, pp. 69-78, Vol. 96.	
	C9	DRUMMOND et al. "Mutations in the bimC box of Cut7 indicate divergence of regulation within the bimC family of kinesin related proteins", <i>Journal of Cell Science</i> , 1998, pp. 853-865, Vol. 111.	
	C10	GAGLIO et al. "Opposing motor activities are required for the organization of the mammalian mitotic spindle pole", <i>Journal of Cell. Biology</i> , 1996, pp. 399-414, Vol. 135.	
	C11	GEIT et al. "The Xenopus laevis aurora-related protein kinase pEg2 associates with and phosphorylates the kinesin-related protein XIEg5", J. Biol. Chem., 1999, pp. 15005-15013, Vol. 274.	
	C12	GEORGE et al. "Current Methods in Sequence Comparison and Analysis", Macromolecular Sequencing and Synthesis, Selected Methods and Applications, 1988, pp. 127-149, Alan R. Liss, Inc.	
	C13	GOLDSTEIN "With apologies to Scheherazade: Tails of 1001 kinesin motors", Annu. Rev. Genet., 1993, pp. 319-351, Vol. 27.	

	Date Considered
--	--------------------

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

\*Applicant's unique citation designation number (prional). \*Applicant is unique citation designation number (priorational). \*Applicant is unique citation designation. \*Applicant is unique citation. \*Applicant is unique citation designation. \*Applicant is unique citation. \*Applicant is unique citation.

Applicam's unique creation designation number (optionis). Projection is to piece a check mark rent is Legislani targuage i instrusion in situation.

This coefficient of information is required by 37 CPR 1.86. The information is required to obtain or retain a benefit by the public which is to file (and by this coefficient) of the projection of the USPTO. Time set lawy depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suppealsors for reducing this burden due to each of the projection of

Alia 2 9 2003

PTO/SB/08B (04-03) Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

020<u>552-003330US</u>

Under the Paper eduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control number Substitute for form 1449/PTO Complete if Known Applicati n Number 10/601.036 INFORMATION DISCLOSURE Filing Date 06/19/2003 STATEMENT BY APPLICANT First Named Inventor Wood, Kenneth W., et. al. Art Unit (use as many sheets as necessary) Examiner Name Т3 of 5

Attomey Docket Number

		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials *	Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-1, No.¹  No.¹			
	C14	HACKNEY "The rate-limiting step in microtubule-stimulated ATP hydrolysis by dimeric kinesin head domains occurs while bound to the microtubule", J. Biol. Chem., 1994, pp. 16508-16511, Vol. 269.		
	C15	HECK et al. "The kinesin-like protein KLP61F is essential for mitosis I Drosophila", Journal of Cell. Biology, 1993, pp. 665-679, Vol. 123.		
	C16	HOPKINS, SETH C. et al. "Inhibitors of Kinesin Activity from Structure-Based Computer Screening", Biochemistry, February 18, 2000; pp. 2805-2814, Vol. 39.		
	C17	HOYT et al. "Two S. cerevisiae kinesin-related gene products required for mitotic spindle assembly", Journal of Cell. Biology, 1992, pp. 109-120, Vol. 118.		
	C18	INOUE, YUICHI, et al; Movements of truncated kinesin fragments with a short or an artificial flexible neck, <i>Proc Natl. Acad, Sci. USA</i> ; July 1997; pp. 7275-7280; Volume 94		
	C19	KAISER et al. "All-trans-Retonic Acid-mediated Growth Inhibition Involves Inhibition of Human Kinesin- related Protein HsEg5", The Journal of Biological Chemistry, July 2, 1999; pp. 18925-18931, Vol. 274, No. 27.		
	C20	KAPOOR et al. "Allele-specific activators and inhibitors for kinesin", Proc. Natl. Acad. Sci., 1999, pp. 9106-9111, Vol. 96, USA.		
	C21	KASHINA et al. "The bimC family of kinesins: essential bipolar mitotic motors driving centrosome separation", Biochim. Biophys. Acta, 1997, pp. 257-271, Vol. 1357.		
	C22	KASHINA et al., "A bipolar kinesin", <i>Nature</i> , 1996, pp. 270-272, Vol. 379.		
	C23	LAZAR, ELIANE, et al.; Transforming Growth Factor α: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities; Molecular and Cellular Biology, March 1988; pp. 1247-1252; Volume 8,No. 3		
	C24	LE GUELLEC et al. "Cloning by differential screening of a Xenopus cDNA that encodes a kinesin- related protein", Mol. Cell Biol., 1991, pp. 3395-3398, Vol. 11		
	C25	LIN, MICHAEL C., et al; Structure Function Relationships in Glucagon: Properties of Highly Purified Des-His -, Monoido, and [Des-Asa <sup>78</sup> , Thr <sup>73</sup> ] (homoserine lactone <sup>97</sup> )-glucagon; <i>Biochemistry</i> , 1975; pp 1559-1563; Volume 14, No. 8		
	C26	LOCKHART et al. "Kinetics and motility of the Eg5 microtubule motor", Biochemistry, 1996, pp. 2365-2373, Vol. 35.		

$\overline{}$	<del></del>		
Exami	er	Date	1
Signati	ire	Considered	1
<u></u>	<del></del>		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

Evolution-to-chain section conditions with the control of the cont minutes to conclusio, including gathering, preparing, and submitting the completed application form to the USPTO. Time will say depending upon the individual case. Any comments on the encount of time vor require to complete dar application form to the USPTO. Time will say depending upon the individual case. Any comments on the encount of time vor require to complete this form and/our suggestions for required plant burden, about the sent to the Chief Information Officer, U.S. Patent and Trademan Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1459, Alexandria, VA 22313-1450.

Page

AUG 2 9 2003

PTO/SB/08B (04-03) Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork stuction Act of 1995) to persons are required to respond to a collection of information unless it contains a valid OMB control number PADEN Substitute for form 1449/PTO Complete if Known **Application Number** 10/601,036 INFORMATION DISCLOSURE Filing Date 06/19/2003 STATEMENT BY APPLICANT Wood, Kenneth W., et. al. First Named Inventor Art Unit (use as many sheets as necessary) Examiner Name Page 14 of 5 Attorney Docket Number 020552-003330US

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), tille of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	C27	MAYER, THOMAS U. et al. "Inhibitor of Mitotic Spindle Bipolarity Identified in a Phenotype-Based Screen", Science, October 26, 1999; pp. 971-974, Vol. 286.	
	C28	RIEGER et al. Glossary of Genetics and Cytogenetics, pp. 17-18, 1976	
	C29	ROOF et al. "Kinesin-related proteins required for assembly of the mitotic spindle", Journal of Cell. Biology, 1992, pp. 95-108, Vol. 188.	
	C30	SAWIN et al. "Mitotic spindle organization by a plus-end-directed microtubule motor", Nature, 1992, pp. 540-543, Vol. 359.	
	C31	SAWIN et al. "Mutations in the kinesin-like protein disrupting localization to the mitotic spindle", <i>Proc. Natl. Acad. Sci.</i> , 1995, pp. 4289-4293, Vol. 92, UDS.	
	C32	SCHWARTZ, GERALD P., et al.; A superactive insulin: [B10-Aspartic acid] insulin (human); Proc. Natl. Acad. Sci USA; September 1987; pp. 6408-6411; Volume 84	
	C33	SHARP et al. "The bipolar kinesin, KLP61F, cross-links microtubules within interpolar microtubule bundles of Drosophila embryonic mitotic spindles", <i>Journal of Cell. Biology</i> , 1999, pp. 125-138, Vol. 144.	
	C34	SKOLNICK et al. "From genes to protein structure and function: novel applications of computational approaches in the genomic era", TIBTECH, 2000, pp. 34-39, Vol. 18	
	C35	WALCZAK et al. "A model for the proposed roles of different microtubule-based motro proteins in establishing spindle polarity", Curr. Biol., 1998, pp. 903-913, Vol. 8.	
	C36	WALCZAK et al. "XKCM1: A Xenopus kinesin-related protein that regulates microtubule dynamics during mitotic spindle assembly", Cell, 1996, pp. 37-47, Vol. 84.	
	C37	WHITEHEAD et al. "Expanding the role of HsEg5 within the mitotic and post-mitotic phases of the cell cycle", Journal of Cell. Science, 1998, pp. 2551-2561, Vol. 111.	
	C38	WHITEHEAD et al. "The spindle kinesin-like protein HsEg5 is an autoantigen in systemic lupus erythematosus", Arthritis and Rheumatism, 1996, pp. 1635-1642, Vol. 39.	
	C39	WHITEHEAD et al., GenBank Accession Number U37426, versions 1151084 and 1171152, 1995.	

Examiner	i i	Date	1
Signature		Considered	1
Colgitature			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

EXAMINEE, Initial if reference considered, whether or not claims in in conformance and not considered. Include copy of them of the most in conformance and not considered. Include copy of them of them of the conformance and not considered. Include copy of them of COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.